Physician profile
Wayne E Williams
NPI 1366544827
$704.95
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $134 · 2021: $220 · 2022: $85.11.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $112.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $77.52 | 2019-2021 | |
| Amarin Pharma, INC. | $67.76 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $54.91 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $46.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.74 | 2019-2020 | |
| Hologic Sales and Service, LLC | $33.84 | 2021-2022 | |
| Pfizer INC. | $28.52 | 2021 | |
| Sunovion Pharmaceuticals INC. | $28.36 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.10 | 2022 | |
| Neurocrine Biosciences, INC. | $15.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.57 | 2020 | |
| Lilly USA, LLC | $14.12 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $13.67 | 2019 | |
| Astellas Pharma US INC | $12.74 | 2019 | |
| Novo Nordisk INC | $12.63 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.23 | 2020 | |
| Cmp Pharma, INC. | $11.85 | 2021 | |
| Eisai INC. | $11.83 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $11.56 | 2021 | |
| Zyla Life Sciences, INC. | $11.26 | 2020 | |
| Tactile Systems Technology INC | $11.24 | 2019 | |
| Merck Sharp & Dohme LLC | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.